Compare HELE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELE | PCRX |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | United States |
| Employees | 1854 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 1.0B |
| IPO Year | 1996 | 2010 |
| Metric | HELE | PCRX |
|---|---|---|
| Price | $37.48 | $36.44 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 9 |
| Target Price | $31.67 | ★ $33.57 |
| AVG Volume (30 Days) | 643.3K | ★ 2.5M |
| Earning Date | 10-08-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 1.69 | 0.89 |
| Revenue | ★ $1,478,845,000.00 | $541,533,000.00 |
| Revenue This Year | $0.95 | $3.84 |
| Revenue Next Year | $1.50 | $4.73 |
| P/E Ratio | ★ $21.51 | $191.58 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $13.85 | $18.80 |
| 52 Week High | $37.79 | $36.67 |
| Indicator | HELE | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.43 | 83.16 |
| Support Level | $25.35 | $24.59 |
| Resistance Level | N/A | $36.45 |
| Average True Range (ATR) | 1.42 | 0.06 |
| MACD | 0.97 | -0.39 |
| Stochastic Oscillator | 86.64 | 86.67 |
Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.